Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated November 21, 2016, is a report of a foreign private issuer filed by Aurinia Pharmaceuticals Inc. The filing incorporates by reference a news release (Exhibit 99.1) regarding clinical trial data presented at the American Society of Nephrology Kidney Week 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates rather than financial performance.
Material Changes and Clinical Updates
The primary material update concerns the global Phase IIB AURA study of voclosporin for the treatment of lupus nephritis. The company highlighted renal function data from this study during the American Society of Nephrology Kidney Week 2016.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the context of the clinical data presentation.
Key Facts for Investor Verification
- Verify the specific renal function data results from the Phase IIB AURA study of voclosporin for lupus nephritis.
- Confirm the full text of the news release incorporated as Exhibit 99.1 for detailed clinical endpoints.
- Note that this filing is incorporated into the Registrant's Registration Statement on Form F-10 (File No. 333-206994).